High blood pressure is a strong risk factor for cardiovascular, cerebrovascular, and kidney disease. Although highly heritable, the genetic basis of blood pressure variation in the general population has been poorly-defined. In preliminary work, a common genetic variant associated with blood pressure was identified at the GUCY1A3/GUCY1B3 locus, which encodes the alpha1 and beta1 subunit of soluble guanylate cyclase, an enzyme which synthesizes cGMP when activated by nitric oxide and which is abundantly expressed in the vasculature. Among up to 200,000 individuals of European ancestry, 58% of the population has two copies of a BP-raising allele. The overall goal of the proposed research program is to ascertain whether the GUCY1A3/GUCY1B3 genetic variant associated with blood pressure (or a closely linked variant) modulates expression of soluble guanylate cyclase alpha1 and/or beta1 subunits.
In Aim 1, we seek to establish whether the association of BP with the SNP at the GUCY1A3/GUCY1B3 locus is likely to be determined by a difference in sGC activity. Inhaled nitric oxide will be administered to individuals with 0 or 2 copies of the BP-raising allele, and the impact of genotype on the ability of NO inhalation to increase plasma cGMP levels will be determined. In parallel experiments, platelet soluble guanylate cyclase subunit mRNA and protein levels, as well as enzyme activity and NO- inhabitable aggregation will be compared between genotypes.
In Aim 2, genetic variants will be introduced into bacterial artificial chromosomes containing the human GUCY1A3/GUCY1B3 locus. Clones containing major and minor alleles will be introduced in vascular smooth muscle cells, and expression of the soluble guanylate cyclase alpha1 and beta1 subunits will be compared. The investigators'proposed use of detailed physiologic phenotyping and molecular characterization of the DNA sequence variation promises to yield fundamental insights into regulation of the GUCY1A3 and GUCY1B3 genes and to begin to better understand the role of nitric oxide-soluble guanylate cyclase-cGMP signaling in blood pressure regulation in the general population.
Given the world-wide prevalence of hypertension and of the genetic variants associated with higher BP, determining that genetic variation identifies individuals with diminished soluble guanylate cyclase-cGMP activity could have important implications for the targeting of individuals for pharmacologic intervention at the population leve.
|(2016) The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. Nat Genet 48:1171-84|
|Wu, Connie; Arora, Pankaj; Agha, Obiajulu et al. (2016) Novel MicroRNA Regulators of Atrial Natriuretic Peptide Production. Mol Cell Biol 36:1977-87|
|Smith, J Gustav; Newton-Cheh, Christopher (2015) Genome-wide association studies of late-onset cardiovascular disease. J Mol Cell Cardiol 83:131-41|
|Hess, Dean R (2015) The evidence is in: noninvasive ventilation saves lives. Crit Care Med 43:927-8|
|Ho, Jennifer E; Arora, Pankaj; Walford, Geoffrey A et al. (2014) Effect of phosphodiesterase inhibition on insulin resistance in obese individuals. J Am Heart Assoc 3:e001001|
|(2014) Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nat Genet 46:826-36|
|Buys, Emmanuel; Sips, Patrick (2014) New insights into the role of soluble guanylate cyclase in blood pressure regulation. Curr Opin Nephrol Hypertens 23:135-42|